Envision a tablet that dissolves in your mouth with a flick of your tongue, relieving you of any trouble. LANSOPRAZOLE 15 MG MOUTH DISSOLVING TABLETS are not just any tablet; these are elaborately formulated tablets designed to disintegrate efficiently when in contact with your tongue. The ingredients, compression, and disintegration properties make these tablets unique from other traditional tablets. Any pharma company that plans to set up its own PCD Pharma Franchise business with a diversification plan, should consider this product.
The composition of Pharma-lansoprazole 15 MG tablet formulation includes compounds of pharmaceutical-grade excipients which are associated with the medication (Lansoprazole 15 MG). The combination of pharmaceutical-grade excipients, including the diluents, superdisintegrants, binders, flavor, sweetener, and other excipients, varies according to the approved formulation for manufacturing a product.
The execution of an optimal design formulation for quick-dissolving tablets requires the preparation of a tablet matrix with good physical strength and fast disintegrating properties. Achieving this balance using functional excipients involves the selection of suitable diluents (for mass and processing characteristics), binders (if necessary), superdisintegrants (for quick disintegration), sweeteners and flavors (for taste) and additional ingredients, if any, to be incorporated.
Since the dose of Lansoprazole in each tablet is less compared to the weight of each tablet, every effort must be made to ensure uniformity in the formulation. Compatibility of the active ingredient (Lansoprazole) with excipient system has to be established before finalization of formulation.
Taste modifiers, if any, must be added to help with mouthfeel. The formulation development will require flavorings and sweeteners to improve tablet palatability.
Preliminary weighing of samples, accurate weighing, and individual verification of each raw material must occur before batch manufacturing begins for the approved formulation. The raw materials may be sieved or milled to obtain granular material of desired quality.
Active drug (Lansoprazole) is then accurately added to the mix and processed to maintain uniformity of distribution throughout the batch. This step is particularly important because Lansoprazole has a low dose in relation to the weight of the tablet.
Depending on the method of manufacturing and other factors such as moisture level, temperature range, and the nature of formulation, the blend is subjected to the technological process. The processing consists of direct compression or the granulation process or other processes. The process parameters such as phase of addition of materials, blending time, granulation technique, and moisture levels are optimized. The physical properties of the mixture such as flow property, bulk density, moisture content, and uniformity should be monitored.
Before compression, the powder blend is subjected to flowability index, bulk density, moisture content and other tests to ensure that the prepared material is suitable for processing through the compression machine. During compression, the weight of each compressed tablet must be maintained within the specified range and any deviation should be investigated as per the standard operating procedures for the manufacturing process.
To obtain the optimized compression force is a key step in formulation development. The tablet must be capable of tolerating handling and packaging without losing its effective disintegrating property. Compression process parameters such as type of compression tooling, compression speed, and compression force need to be optimized during formulation development.
The quality control parameters of tablets such as hardness, size, weight variation, friability, etc. should be studied and maintained within the limit.
The disintegration of each lot of the tablet must also meet the specification as per the standard.
The morphology of the tablet also affects the tablet surface, shape, color uniformity, etc. The appearance of the tablet must be checked for any form of defect such as capping, chipping, etc. which may be related to the process of compression or compression speed or powder handling.
All these quality parameters of optimized manufacturing process control during production ensure desirable properties of tablets over different batches.
The tablet should be found to have passed the specifications laid out for the approved formulation, i.e., the oral dose unit, average weight, friability, hardness, thickness, disintegration, and dissolution (formulation-specific test). These tests will indicate the physical quality of the tablet, grain strength, and other properties. The product should have shown stability in comparison to the specifications of the formulation and during the flow process from the product level and tablet level. The moisture content of the tablet can determine the stability of the product because high levels of humidity during storage can result in inadequate disintegration of tablets.
Analysis of stability studies of the product during storage conditions will ensure optimal behavior over its life cycle. The nature of the condition also affects the stability of the product, i.e., any adverse conditions like moist conditions can affect the physical and chemical state of the tablet.
The impact of packaging materials for protection against moisture (unit dose blister packaging) is also assessed. The process parameters have been tested for moisture entry and prevention. The expiry date on the packaging confirms the behavior of the product with the packaging condition.
The product shall undergo the qualitative and quantitative identification for Lansoprazole 15 MG. To check for the quantitative amount of the active substance by using validated analytical techniques, the following tests will provide the physical quality of the overall product.
Analysis of the product shall include tests such as specific tests for Active Pharmaceutical Ingredient content, Average weight, Disintegration, Friability, Hardness, Disintegration, Dissolution, and other tests suitable for tablets prescribed in the approved formulation. So the evaluated parameters give an overview of physical properties and product performance.
The appearance, quantitative content, degradation, disintegration, and the physical state of the product are monitored during stability studies. Water vapor, cooling, and humidity are responsible for changes in the physical state and functioning of the product. Regular analysis through monitored tests in storage monitoring ensures the stability of the product till expiry.
High levels of water vapor in the environment can be responsible for the instability of the product. The high moisture content can change the physical state of the product leading to inadequate disintegration. During storage of the product, its packaging material will be responsible for its stability.
The packaging material should be of sufficient thickness to restrict entry of water vapor. The wrapper for the product should be stable under conditions of exposure to humidity and water vapor. The tablet should possess its desired shape and surface for a period of at least 2 years and should be checked for any changes leading to capping, chipping, and/or an increased level of moisture.
When packaged in unit-dose blister packs, the product shall have a barrier to moisture ingress. The packaging specifications and laboratory mark limits will represent the product integrity.
The API Loading, Blend Uniformity, Compression, Analytical tests, Stability studies, appropriate packaging, and blister packaging for barriers against moisture ingress all contribute to an integrated process to develop a professional portfolio. These would be standardized for all the formulations for copying in other formulations as well.
If the portfolio includes other pharma dosage forms such as capsules, liquids, etc., all the materials, storage conditions, packaging, etc., should be taken into consideration to standardize the requirements for commonality. When required, the graphics and color codes should be maintained uniformly. Thus, the professional portfolio can be developed for an individual manufacturer, distributor, or marketing company. When added to PCD Pharma Franchise business plans, the portfolio will be managed for a seamless platform.
Lansoprazole 15 MG Mouth Dissolving Tablets with formulation, manufacturing, quality testing, stability, packaging and PCD Pharma Franchise details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech